Berkshire Hathaway Inc Class B vs Recursion Pharmaceuticals Inc — how do they compare? Berkshire Hathaway Inc Class B trades at $509.36, while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Berkshire Hathaway Inc Class B is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| BRK.B | RXRX | |
|---|---|---|
Sector | Financials | Health |
52-Week High | $529.65 | $6.79 |
52-Week Low | $465.39 | $2.84 |
Market Cap | — | $1.81B |
Enterprise Value | — | $1.33B |
Signals from Pluang's Aura AI — not financial advice
BRK.B trades at $509.58, down 3.79% on the day, with technical indicators showing a bullish trend from moving averages and strong directional momentum (ADX). Analyst consensus is positive with 57% buy ratings and no sell recommendations. The stock is near key support at $510 and resistance at $522, indicating a critical price zone.
The outlook remains favorable given strong institutional support and bullish technicals, but risks include market volatility and Berkshire Hathaway's exposure to economic cycles. Upside potential hinges on execution across its diversified holdings, while any broad market downturn could pressure the stock.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Trailing returns across standard periods
Latest headlines on both assets
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →